IRD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Opus Genetics (IRD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has positive catalysts such as FDA acceptance of its sNDA, a global licensing agreement with Viatris, and strong hedge fund buying trends. Despite a drop in revenue, the company's net income has significantly improved, and analysts have issued favorable ratings with a high price target. Technical indicators also show bullish moving averages, suggesting potential upward movement.
The MACD is negative and expanding, indicating bearish momentum, but RSI is neutral at 58.653. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the price is currently above the pivot point of 3.612, with resistance at 3.87 and support at 3.354. These factors suggest a potential upward trend in the near term.
FDA acceptance of sNDA for phentolamine ophthalmic solution with a PDUFA goal date in October
Positive Phase 3 trial results for the drug without serious adverse events.
Global licensing agreement with Viatris for U.S. commercialization.
Hedge funds are significantly increasing their positions, with a 2167.49% increase in buying activity last quarter.
Revenue dropped by 20.38% YoY in Q3
EPS decreased by 13.79% YoY, reflecting weaker profitability.
No recent congress trading data or valuation data available.
In Q3 2025, revenue dropped by 20.38% YoY to $3,079,000. However, net income improved significantly, increasing by 131.92% YoY to -$17,454,000. EPS declined by 13.79% YoY to -0.25, while gross margin remained steady at 100%.
LifeSci Capital initiated coverage with an Outperform rating and an $8 price target, while B. Riley issued a Buy rating with a $9 price target. Both ratings suggest significant upside potential from the current price of $3.63.
